18 results about "Exogenous antigen" patented technology

The present application relates to the technical field of bioengineering, and particularly relates to a pIX region antigen-carrying capsid armed adenovirus, a construction method and application. An exogenous antigen gene is introduced into a pIX region of a minor capsid protein of a type 5 adenovirus to form a capsid armed adenovirus; the type 5 adenovirus specifically has an E1 region and an E3 region deletion. The construction method uses pIX as a display platform, can present an exogenous antigen on the virus surface with high density and high repeatability, greatly improves the effective concentration of the antigen, and is expected to induce stronger and more persistent specific immune responses; the modified pIX protein has less influence on the packaging, assembly, structural stability of the virus and the infection ability on target cells; the adenovirus can realize the dual functions of "gene delivery" and "surface antigen presentation", and provides an innovative technical platform for developing multifunctional and high-titer vaccines or gene therapy drugs.

Described herein are recombinant Kluyveromyces lactis (K. lactis) yeasts which are capable of the highly efficient expression of one or more foreign proteins and are suitable for use as a vaccine for generating a protective immune response against pathogens. The invention provides in particular K. lactis strains for the targeted cloning of foreign antigen-coding nucleic acids into the yeast genome of the K. lactis strain, which is characterized in that the K. lactis strain has integrated expression cassettes for foreign antigens as an alternative or in addition to the KILAC4 locus on the KIURA3-20 locus (KLLA0E22771g) and / or on the KIMET5-1 locus (KLLA0B03938g). The invention further relates to integrative expression vectors and to methods for producing the K. lactis strains of the invention as well as to the use thereof as vaccines.

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.

The invention relates to a tumor immunotherapy method based on a Mn-DNA nano vaccine. The invention provides a nano-particle for tumor immunotherapy. The nano-particle comprises metal ions Mn < 2 + >, exogenous dsDNA, antigen peptide and targeting peptide. The invention also provides a method for preparing the nanoparticles, a vaccine or a pharmaceutical composition containing the nanoparticles, application of the nanoparticles and the vaccine or the pharmaceutical composition in tumor immunotherapy, and the like. The nanoparticles can be accurately delivered to antigen presenting cells, so that the antigen presenting cells are promoted to be mature, the antigen presenting capability is enhanced, and the tumor targeting property and the anti-tumor activity are remarkably enhanced. The raw materials used in the invention can be degraded in vivo, and the biosafety is high.

The present disclosure provides oral antigenic compositions comprising a recombinant Spirulina comprising at least one exogenous antigenic epitope. Oral antigenic compositions of the present disclosure can be used as vaccines. Oral antigenic compositions of the present disclosure can be used to induce a protective immune response to infectious microorganism, tumor antigens, or self-antigens.

The application provides a kind of construction and application of multi-stage targeted carrier of viral antigen and adjuvant.It is a kind of nanometer loading SARS-CoV-2 and other viral recombinant protein antigens and vaccine adjuvant Toll-like receptor agonists by using liposome, solid lipid nanoparticle, nanoemulsion, polymer micelle and nanocapsule, etc., the surface of the nanocarrier is modified by using mannose and cationic peptide Par, and the nanocarrier is endowed with multi-stage targeting of dendritic cells and endoplasmic reticulum.By adjusting the ratio of Man and Par, the processing of SARS-CoV-2 and other viral recombinant protein antigens in the endoplasmic reticulum and lysosome of DC cells can be effectively regulated, the presentation of exogenous antigens by DC cells is enhanced, and the initiation of CD8+ and CD4+ T cells in the body is promoted; meanwhile, the nanocarrier can also deliver very low dose of CpG-OND adjuvant directly to the endoplasmic reticulum of DC cells to play a role, and the potential immunotoxicity induced by the adjuvant is reduced.

The present disclosure provides Smart CAR systems in which an exogenous antigen is labeled on a tumor cell, the tumor cell labeled with the exogenous antigen can be recognized by an engineered immune cell expressing a chimeric receptor, the chimeric receptor comprising a binding domain that binds to the exogenous antigen, and the tumor can be at least partially eliminated. The present disclosure also provides methods of preparation, methods of treatment, and uses associated with the Smart CAR system.

The present disclosure provides a Smart CAR system, where an exogenous antigen is labeled on tumor cells, the tumor cells labeled with the exogenous antigen can be recognized by engineered immune cells that express a chimeric receptor comprising a binding domain that binds the exogenous antigen, and the tumor can be eliminated at least in part. The present disclosure also provides methods of preparation, methods of treatment, and uses related to the Smart CAR system.

This invention discloses a sodium caseinate-based Pickering emulsion, its preparation method, and its application, belonging to the field of vaccine adjuvant technology. This invention is the first to propose using Salmonella Typhimurium flagellin and sodium caseinate as raw materials to formulate a Pickering emulsion. The prepared Pickering emulsion has the characteristics of small particle size, good biocompatibility, and high stability, and can induce a high immune response in the body. This invention is also the first to propose the application of the Pickering emulsion formulated using Salmonella Typhimurium flagellin and sodium caseinate as raw materials as a vaccine adjuvant. The Pickering emulsion prepared by this invention has a simple preparation process, requiring only mixing and homogenization, and can effectively load the model antigen OVA. This emulsion has good cellular safety and can promote the endocytosis of exogenous antigens by macrophages. The emulsion can induce the body to produce high levels of antibody titers, with antibody titers reaching more than 120,000 times.

The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and / or lysine.

A method of use of a synthetic SCGB, and compositions thereof, to prevent the development or reduce the development of antibodies against a foreign antigen or set of antigens in the subject that receives the antigen(s) is provided. A synthetic SCGB being recombinant human CC10 protein is provided. The foreign antigen(s) is / are a cell, tissue or organ from a donor subject is administered, introduced, or transplanted into a recipient subject, a lung transplant, transplanted kidney, heart, liver, hematopoietic cell, or any other tissue or organ, antigen(s) is / are from human or non-human origin, purified therapeutic proteins or other drugs, food or drink, self-antigen or an allergen.

The invention relates to the technical field of biological medicines, and provides a method for enhancing the colon cancer resisting function of a V delta 1 gamma delta T cell, and a CDK1 activator and the T cell are combined to prepare a colon cancer resisting medicine. According to the technical scheme, a molecular mechanism for regulating and controlling tumor antigen ectopic expression through the CDK1-NCL axis is illustrated, and the key theory blank of recognizing tumor cells through the V delta 1 gamma delta T cells is filled up; a CDK1 activator TC11 is developed to serve as an auxiliary means for enhancing the functions of the V delta 1 gamma delta T cells, and the limitation that traditional immunotherapy depends on exogenous antigen modification is broken through; in-vivo and in-vitro experiments prove that targeting CDK1 can remodel a tumor immune microenvironment, and a convertible clinical application scheme is provided for combined immunotherapy of colon cancer and other solid tumors.

A dendritic cell (DC)-targeting M13 phage vaccine platform is provided herewith, where spy-tagged neoantigens can be attached to the phage surface with spy-catchers. By expressing DC-targeting peptides and spy-catchers as foreign antigens on the phage surface, its therapeutic and antigenic properties can be enhanced to combat solid cancers. SLS-spy catcher phage (SCP), with or without neoantigen conjugation, significantly repressed tumour growth by boosting systemic anti-tumour immunity and increasing intratumoral infiltration of both innate and adaptive immune cells. Intratumoral administration of SCP also hugely reduced PDL1 expression on tumour cells, making them more susceptible to immune attacks. Additionally, SCP administration restricted the size of blood vessels inside the tumour mass, suggesting multiple factors contribute to restrict tumour growth.

The invention discloses a non-antigen-dependent antibody rapid enhancement method and application, and relates to the technical field of biology. The method comprises the following steps: applying a non-antigen-dependent antibody rapid enhancer to an organism containing a pre-stored antibody in vivo so as to increase the content of the pre-stored antibody; the non-antigen-dependent antibody rapid enhancer comprises lipid nanoparticles coated with single-stranded oligonucleotide, the nucleotide sequence of the single-stranded oligonucleotide is as shown in SEQ ID NO. 1. According to the method, the level of the pre-stored antibody can be rapidly and remarkably improved in the body with the established immune memory under the condition that the exogenous antigen is completely not required to be stimulated again. The limitation that an existing antibody enhancement strategy must depend on antigens is broken through, and a brand-new technical tool and solution with wide application prospects are provided for quick awakening of vaccine efficacy, emergency enhancement of immune defense and controllable adjustment of in-vivo antibody level in antibody preparation.

The present invention provides a vaccine composition for reducing the size or volume of a target tissue, comprising genetic material encoding a foreign antigen, and preferably, the composition can be provided as a vaccine composition for treating or preventing obesity. The vaccine composition can also be provided as a composition for removing subcutaneous adipocytes.

The invention relates to the technical field of medical vaccines, and discloses an immune composition of an erythrocyte-assisted hydrotalcite-based nano vaccine as well as a preparation method and application of the immune composition, the immune composition comprises aged erythrocytes and a hydrotalcite-based nano vaccine coated with a fresh erythrocyte membrane, and the hydrotalcite-based nano vaccine comprises a hydrotalcite-based adjuvant and an exogenous antigen. According to the preparation method and application of the immune composition of the hydrotalcite-based nano vaccine assisted by red blood cells in different states, efficient DC cell antigen cross presentation can be induced in the spleen, exogenous antigen specific immunostimulation is promoted, immune response of T cells is activated, solid tumor growth is directly inhibited, and the tumor volume inhibition rate reaches 60%.

The present invention relates to a vaccine composition for reducing the size or volume of a target tissue, containing a genetic material that encodes a foreign antigen and, preferably, the composition can be provided as a vaccine composition for treating or preventing obesity. The vaccine composition can be provided as a composition for removing subcutaneous adipocytes.

The invention discloses a multivalent vaccine for preventing chicken bursa of Fabricius, Newcastle disease and avian influenza and a preparation method of the multivalent vaccine, and belongs to the field of veterinary vaccines. The technical problem to be solved by the invention is how to effectively prevent and / or treat chicken bursal disease virus, Newcastle disease virus and / or avian influenza virus infection. In order to solve the technical problem, the invention provides recombinant HVT containing coding genes of infectious chicken bursal disease virus VP2 protein, Newcastle disease virus F protein and / or avian influenza virus H9N2HA protein. The recombinant HVT provided by the invention can realize multi-linked immunization, after the recombinant rHVTVP2-F-HA virus infects a host cell, an exogenous antigen and HVT self protein are co-expressed, and T cells and B cells are presented and activated through MHC-I and MHC-II ways, so that immune memory aiming at exogenous pathogens of chicken bursal disease virus, Newcastle disease virus and avian influenza virus and / or HVT is formed.